News

Focus on Tools for the Research, Drug Discovery and Cell Therapy Markets.

The European Patent Office (EPO) upholds bit.bio's patent for its dual genomic safe harbour technology, opti-ox™, securing the bro...

bit.bio's ioSensory Neurons pain research was selected for presentation at SfN’s Neuroscience 2024 press conference.

bit.bio Wins Honours for Innovation in Synthetic Biology and Exceptional Business Growth.

bit.bio appoints new Chief Financial Officer, Przemek Obloj

bit.bio launches panel of 16 neurodegenerative disease models for research and drug discovery in Alzheimer’s and Parkinson’s disea...

bit.bio launches ioAstrocytes, advancing how scientists can model the human brain.

Bi/ond and bit.bio collaboration offers a significant advancement for DMD research and drug discovery.